Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
Prednisone reduces the risk of developing TB-IRIS after starting antiretroviral treatment

Prednisone reduces the risk of an immune restoration inflammatory syndrome (IRIS) in people with HIV after starting tuberculosis (TB) treatment, a randomised trial called PredART has found.

Published
20 February 2017
By
Keith Alcorn
Three-drug regimen beats XDR-TB in first trial

A regimen of three oral drugs given for six months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have

Published
17 February 2017
By
Keith Alcorn
Isoniazid preventive treatment reduces the risk of death by 37% in people living with HIV

A six-month course of isoniazid preventive treatment (IPT) at the beginning of the Temprano trial in Ivory Coast reduced the risk of death by 37% over

Published
16 February 2017
By
Keith Alcorn
New tuberculosis therapy could be more potent than current treatments

Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.

Published
26 January 2017
From
UCLA
Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug

While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.

Published
26 January 2017
From
MSF Access Campaign
The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical development of tuberculosis (TB) drug candidate sutezolid. The antibiotic sutezolid has long been considered a promising investigational treatment that, if further developed in combination with other drugs, could be used to more effectively treat both drug-sensitive and drug-resistant TB in patients.

Published
25 January 2017
From
Medicines Patent Pool
Indian Woman Wins Right to Use Last-Resort Tuberculosis Drug

An 18-year-old woman and her family have won a battle in an Indian court to gain access to a restricted tuberculosis drug that her doctors say she needs to survive.

Published
24 January 2017
From
Wall Street Journal (blog)
Person-to-person contact may cause most drug-resistant TB cases

The worst form of drug-resistant tuberculosis isn't just arising from inadequate treatment, it's mostly being spread from person to person, according to a new study of hundreds of cases in South Africa.

Published
23 January 2017
From
Reuters
In the era of universal treatment, what are HIV clinical guidelines for?

The purpose and structure of clinical HIV guidelines may have to change radically now that universal treatment on diagnosis is the clinical consensus, physicians from the European

Published
22 December 2016
By
Gus Cairns
IDSA Guidelines Recommend Newer Tests to Diagnose Tuberculosis

Patients at risk for latent or active tuberculosis (TB) infection should be assessed with newer tests, including interferon-gamma release assays (IGRAs) and molecular diagnostics, recommend guidelines on TB diagnosis developed by the American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA) and Centers for Disease Control and Prevention (CDC) and published in the journal Clinical Infectious Diseases. Advances in testing prompted the first new guidelines on TB diagnosis in 17 years.

Published
19 December 2016
From
IDSA
← First12345...102Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.